3D Medicines (HKSE:01244) Additional Paid-In Capital : HK$5,234.1 Mil(As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Additional Paid-In Capital?

3D Medicines's quarterly additional paid-in capital declined from Dec. 2022 (HK$4,721.4 Mil) to Jun. 2023 (HK$4,633.8 Mil) but then increased from Jun. 2023 (HK$4,633.8 Mil) to Dec. 2023 (HK$5,234.1 Mil).

3D Medicines's annual additional paid-in capital increased from Dec. 2021 (HK$0.0 Mil) to Dec. 2022 (HK$4,721.4 Mil) and increased from Dec. 2022 (HK$4,721.4 Mil) to Dec. 2023 (HK$5,234.1 Mil).

3D Medicines Additional Paid-In Capital Historical Data

The historical data trend for 3D Medicines's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Additional Paid-In Capital Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

4,721.36

5,234.10

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial			-	-	4,721.36	4,633.84	5,234.10

3D Medicines Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

3D Medicines Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines